ResMed Statistics
Total Valuation
ResMed has a market cap or net worth of $31.49 billion. The enterprise value is $30.92 billion.
| Market Cap | 31.49B |
| Enterprise Value | 30.92B |
Important Dates
The next confirmed earnings date is Thursday, April 30, 2026, after market close.
| Earnings Date | Apr 30, 2026 |
| Ex-Dividend Date | Feb 12, 2026 |
Share Statistics
ResMed has 145.04 million shares outstanding. The number of shares has decreased by -0.43% in one year.
| Current Share Class | 145.04M |
| Shares Outstanding | 145.04M |
| Shares Change (YoY) | -0.43% |
| Shares Change (QoQ) | -0.36% |
| Owned by Insiders (%) | 0.52% |
| Owned by Institutions (%) | 76.01% |
| Float | 144.15M |
Valuation Ratios
The trailing PE ratio is 21.48 and the forward PE ratio is 18.67. ResMed's PEG ratio is 1.36.
| PE Ratio | 21.48 |
| Forward PE | 18.67 |
| PS Ratio | 5.83 |
| Forward PS | n/a |
| PB Ratio | 5.00 |
| P/TBV Ratio | 11.07 |
| P/FCF Ratio | 17.58 |
| P/OCF Ratio | 16.45 |
| PEG Ratio | 1.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.27, with an EV/FCF ratio of 17.26.
| EV / Earnings | 20.81 |
| EV / Sales | 5.73 |
| EV / EBITDA | 15.27 |
| EV / EBIT | 16.76 |
| EV / FCF | 17.26 |
Financial Position
The company has a current ratio of 3.06, with a Debt / Equity ratio of 0.13.
| Current Ratio | 3.06 |
| Quick Ratio | 1.97 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | 0.41 |
| Debt / FCF | 0.47 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 25.68% and return on invested capital (ROIC) is 26.60%.
| Return on Equity (ROE) | 25.68% |
| Return on Assets (ROA) | 14.75% |
| Return on Invested Capital (ROIC) | 26.60% |
| Return on Capital Employed (ROCE) | 25.44% |
| Weighted Average Cost of Capital (WACC) | 9.11% |
| Revenue Per Employee | $540,894 |
| Profits Per Employee | $148,885 |
| Employee Count | 9,980 |
| Asset Turnover | 0.69 |
| Inventory Turnover | 2.15 |
Taxes
In the past 12 months, ResMed has paid $332.81 million in taxes.
| Income Tax | 332.81M |
| Effective Tax Rate | 18.30% |
Stock Price Statistics
The stock price has decreased by -7.94% in the last 52 weeks. The beta is 0.93, so ResMed's price volatility has been similar to the market average.
| Beta (5Y) | 0.93 |
| 52-Week Price Change | -7.94% |
| 50-Day Moving Average | 235.72 |
| 200-Day Moving Average | 256.38 |
| Relative Strength Index (RSI) | 34.73 |
| Average Volume (20 Days) | 987,634 |
Short Selling Information
The latest short interest is 11.49 million, so 7.93% of the outstanding shares have been sold short.
| Short Interest | 11.49M |
| Short Previous Month | 11.85M |
| Short % of Shares Out | 7.93% |
| Short % of Float | 7.97% |
| Short Ratio (days to cover) | 11.56 |
Income Statement
In the last 12 months, ResMed had revenue of $5.40 billion and earned $1.49 billion in profits. Earnings per share was $10.11.
| Revenue | 5.40B |
| Gross Profit | 3.32B |
| Operating Income | 1.85B |
| Pretax Income | 1.82B |
| Net Income | 1.49B |
| EBITDA | 2.02B |
| EBIT | 1.85B |
| Earnings Per Share (EPS) | $10.11 |
Balance Sheet
The company has $1.42 billion in cash and $847.72 million in debt, giving a net cash position of $569.35 million or $3.93 per share.
| Cash & Cash Equivalents | 1.42B |
| Total Debt | 847.72M |
| Net Cash | 569.35M |
| Net Cash Per Share | $3.93 |
| Equity (Book Value) | 6.32B |
| Book Value Per Share | 43.39 |
| Working Capital | 2.57B |
Cash Flow
In the last 12 months, operating cash flow was $1.91 billion and capital expenditures -$122.89 million, giving a free cash flow of $1.79 billion.
| Operating Cash Flow | 1.91B |
| Capital Expenditures | -122.89M |
| Depreciation & Amortization | 179.49M |
| Net Borrowing | -10.00M |
| Free Cash Flow | 1.79B |
| FCF Per Share | $12.35 |
Margins
Gross margin is 61.47%, with operating and profit margins of 34.19% and 27.53%.
| Gross Margin | 61.47% |
| Operating Margin | 34.19% |
| Pretax Margin | 33.69% |
| Profit Margin | 27.53% |
| EBITDA Margin | 37.51% |
| EBIT Margin | 34.19% |
| FCF Margin | 33.19% |
Dividends & Yields
This stock pays an annual dividend of $2.40, which amounts to a dividend yield of 1.11%.
| Dividend Per Share | $2.40 |
| Dividend Yield | 1.11% |
| Dividend Growth (YoY) | 12.56% |
| Years of Dividend Growth | 14 |
| Payout Ratio | 23.04% |
| Buyback Yield | 0.43% |
| Shareholder Yield | 1.53% |
| Earnings Yield | 4.72% |
| FCF Yield | 5.69% |
Analyst Forecast
The average price target for ResMed is $292.56, which is 34.73% higher than the current price. The consensus rating is "Buy".
| Price Target | $292.56 |
| Price Target Difference | 34.73% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
| Revenue Growth Forecast (5Y) | 8.52% |
| EPS Growth Forecast (5Y) | 10.86% |
Stock Splits
The last stock split was on August 31, 2010. It was a forward split with a ratio of 2:1.
| Last Split Date | Aug 31, 2010 |
| Split Type | Forward |
| Split Ratio | 2:1 |
Scores
ResMed has an Altman Z-Score of 12.89 and a Piotroski F-Score of 6.
| Altman Z-Score | 12.89 |
| Piotroski F-Score | 6 |